Transdermally absorbable preparation
A transdermally absorbable preparation that even when a drug with poor solubility in a base is added in high concentration, is stable over time and can suppress crystallization of the drug, excelling in transdermal absorbability. There is provided a transdermally absorbable preparation, comprising a base and, added thereto, at least composite particles which are composed of a silicate compound and an organic acid and a drug.
1. A transdermally absorbable preparation comprising a base, wherein the base comprises composite particles composed of micro particles of a silicate compound and one or more ingredient(s), wherein the one or more ingredients comprises at least one or more drug(s) and one or more organic acid(s) and/or one or more pharmaceutically acceptable salt(s) thereof, wherein the one or more drug(s) is/are a risperidone and/or an olanzapine and the one or more organic acid(s) is/are selected from a group consisting of acetic acid, propionic acid, a butyric acid, a lactic acid, a benzoic acid, and a salicylic acid, and wherein the one or more ingredient(s) is/are physically adsorbed on the surface of the micro particles of the silicate compound.
2. The transdermally absorbable preparation according to claim 1 , wherein the silicate compound is a silicic anhydride.
3. The transdermally absorbable preparation according to claim 1 , wherein the base is a lipophilic base.
4. The transdermally absorbable preparation according to claim 3 , comprising a styrene/isoprene/styrene block copolymer and/or an acrylic pressure-sensitive adhesive base as the lipophilic base.
5. The transdermally absorbable preparation according to claim 1 further comprising one or more kinds selected from a group consisting of a propylene glycol monolaurate, an isostearyl alcohol, a lauric acid diethanolamide, an isopropyl myristate, a capric acid and a sorbitan monolaurate as a transdermal absorption enhancer.
6. The transdermally absorbable preparation according to claim 2 , wherein the one or more drug(s) is a risperidone and the one or more organic acid(s) is an acetic acid.
7. The transdermally absorbable preparation according to claim 6 , comprising styrene/isoprene/styrene block copolymer and/or an acrylic pressure-sensitive adhesive base as a lipophilic base.
8. The transdermally absorbable preparation according to claim 7 , further comprising one or more kinds selected from a group consisting of a propylene glycol monolaurate, an isostearyl alcohol, a lauric acid diethanolamide, an isopropyl myristate, a capric acid and a sorbitan monolaurate as a transdermal absorption enhancer.
9. The transdermally absorbable preparation according to claim 7 , wherein the lipophilic base is styrene/isoprene/styrene block copolymer.
10. The transdermally absorbable preparation according to claim 9 , further comprising one or more kinds selected from a group consisting of a propylene glycol monolaurate, an isostearyl alcohol, a lauric acid diethanolamide, an isopropyl myristate, a capric acid and a sorbitan monolaurate as a transdermal absorption enhancer.
11. A transdermally absorbable preparation comprising a base and one or more drug(s), wherein the base comprises composite particles composed of micro particles of a silicate compound and one or more ingredient(s), wherein the one or more ingredients comprises at least one or more organic acid(s) and/or one or more pharmaceutically acceptable salt(s) thereof, wherein the one or more drug(s) is/are a risperidone and/or an olanzapine and the one or more organic acid(s) is/are selected from a group consisting of acetic acid, propionic acid, a butyric acid, a lactic acid, a benzoic acid, and a salicylic acid, and wherein the one or more ingredient(s) is/are physically adsorbed on the surface of the micro particles of the silicate compound.